Swine Reproductive and Respiratory Syndrome Vaccine Market Size, Share, Growth and Industry Analysis by Type (Activated Vaccine, And, Inactivated Vaccine), By Application (Government Tender, And, Market Sales), Regional Insights and Forecast to 2031

Updated On: 22 April 2024

SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET OVERVIEW

• 

• Request a Free Sample to learn more about this report

The global swine reproductive and respiratory syndrome vaccine market size was USD 385.1 million in 2021 and the market is projected to touch USD 1121.13 million by 2031, exhibiting a CAGR of 10.2% during the forecast period.

Swine Reproductive and Respiratory Syndrome (PRRS) is a viral disease affecting pigs globally. The syndrome, caused by PRRS virus strains, manifests in two forms: reproductive issues in breeding sows and respiratory problems in pigs of all ages. PRRS weakens the immune system, making pigs susceptible to secondary infections. The virus spreads easily within swine herds, posing significant economic challenges for the pork industry due to reduced reproductive efficiency and increased mortality rates.

Control measures involve vaccination, biosecurity practices, and management strategies to mitigate the impact of this complex and economically impactful disease on swine production. All of these factors have played an important role in increasing swine reproductive and respiratory syndrome vaccine market growth.

COVID-19 impact: Disruption in Supply Chains during Pandemic Decreased Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The COVID-19 pandemic had multifaceted effects on swine reproductive and respiratory syndrome (PRRS). Disruptions in the supply chain and workforce limitations hindered access to veterinary care and vaccinations, potentially exacerbating PRRS challenges. Reduced global trade and transportation restrictions further complicated disease management. Conversely, heightened awareness of biosecurity measures emerged as a positive outcome, aiding in PRRS prevention. The pandemic-induced disruptions underscored the importance of resilient and adaptable strategies in swine production systems to mitigate the impact of both PRRS and external shocks on the industry.

LATEST TRENDS

"Usage of Molecular Techniques like PCR Assays to Fuel Market Growth"

Recent innovations in swine reproductive and respiratory syndrome (PRRS) focus on advancing diagnostics and prevention. Molecular techniques like PCR assays enable quicker and more accurate PRRS virus detection. Vaccination strategies have evolved with the development of novel, more effective vaccines to combat diverse PRRS virus strains.

Advanced genetic selection methods contribute to breeding pigs with enhanced resistance to PRRS. Additionally, research into antiviral treatments and immune-modulating approaches offers promising avenues for managing PRRS outbreaks. These innovations collectively aim to improve disease surveillance, control, and resilience within swine production, fostering a more sustainable and disease-resistant future.

SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET SEGMENTATION

• 

• Request a Free Sample to learn more about this report

• By Type:

The market can be divided on the basis of type into the following segments:

Activated vaccine and inactivated vaccine. The activated vaccine segment is projected to hold the dominant market share through 2031 the forecasting period.

The activated vaccine segment in the swine reproductive and respiratory syndrome vaccine market involves inactivated or modified live virus vaccines. These vaccines stimulate the pig's immune system to produce a protective response against PRRS. Widely used in swine farming, activated vaccines play a crucial role in preventing and controlling the impact of PRRS on pig population.

• By Application:

The market can be divided on the basis of application into the following segments:

Government tender, and, market sales. The government tender segment is predicted to dominate the market through 2031.

In the swine reproductive and respiratory syndrome vaccine market, the government tender segment pertains to procurement contracts initiated by governmental bodies for vaccine supply. These tenders are essential for mass vaccination programs aimed at controlling and preventing PRRS outbreaks in swine populations. The government's involvement ensures widespread vaccine distribution and adherence to disease control protocols in the swine industry.

DRIVING FACTORS

"High Herd Density and Swine Industry Intensification to Amplify Market Growth"

Swine reproductive and respiratory syndrome (PRRS) dynamics are driven by several factors. High herd density and swine industry intensification contribute to rapid virus transmission. Global trade and movement of pigs facilitate the spread of PRRS strains. The virus's ability to mutate further complicates control measures. Inadequate biosecurity practices and varying management protocols across farms also play a role.

Climate conditions, particularly temperature and humidity, influence the virus's survival and transmission. Economic factors, such as production costs and market demands, impact the industry's ability to implement advanced disease prevention strategies. These multifaceted factors collectively shape the prevalence and impact of PRRS in swine populations. The above-mentioned factors are driving the swine reproductive and respiratory syndrome vaccine market share.

"Higher Market Demand for Leaner Pork to Drive Market Growth"

Market demand for leaner pork and high pig productivity acts as a driving force in swine reproductive and respiratory syndrome (PRRS). Intensive breeding practices aimed at meeting these demands increase the risk of disease transmission. The movement of breeding stock and genetic materials globally amplifies the exposure to diverse PRRS virus strains.

Farm-to-farm variability in biosecurity standards and vaccination protocols influences the disease's prevalence. Additionally, the persistent nature of the PRRS virus, its ability to establish reservoirs in pig populations, and the challenges in developing broadly effective vaccines contribute to the complexity of managing and controlling PRRS in the swine industry.

RESTRAINING FACTOR

"Inconsistent Implementation of Biosecurity Measures to Deteriorate Market Growth"

Several factors act as constraints in managing swine reproductive and respiratory syndrome (PRRS). The virus's ability to mutate results in evolving strains, complicating vaccine development and efficacy. Inconsistent implementation of biosecurity measures across farms hinders effective disease control. Diagnostic challenges and the lack of rapid, universally applicable tests limit timely identification of PRRS cases.

Economic considerations, including the costs of vaccination and disease management, may pose barriers for some producers. Global trade dynamics and movement restrictions impact the industry's ability to prevent the introduction of new PRRS strains. These restraining factors collectively contribute to the ongoing challenges in mitigating the impact of PRRS on swine populations.

SWINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE REGIONAL INSIGHTS

• 

• Request a Free Sample to learn more about this report

"Asia Pacific to Dominate Market Due to Intensive Pig Farming "

The leading region in swine reproductive and respiratory syndrome vaccine is Asia Pacific. China, with its substantial pig population and central role in the pork industry, often faces significant challenges related to PRRS. Intensive pig farming and high-density areas in Asia Pacific also contribute to the prevalence of PRRS.

The dynamic nature of the swine industry, coupled with global trade, underscores the widespread impact of PRRS. Efforts to combat the syndrome require international collaboration, emphasizing the need for a comprehensive approach to disease management on a global scale.

Key Industry Players

"Leading Players adopt Acquisition Strategies to Stay Competitive "

Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market.

List of Market Players Profile

• ASCENT CORPORATION (Japan)
• Boehringer-Ingelheim (Germany)
• MSD Animal Health (U.S.)
• SPAH (South Korea)
• Ceva (France)
• Chengdu TECH-BANK Biological Products Co., Ltd (China)
• Ringpu (China)
• QILU ANIMAL HEALTH PRODUCTS CO., LTD (China)
• DAHUANONG (China)
• CAVAC (Vietnam)
• Komipharm (South Korea)
• Agrovet (Peru)
• Bioveta (Czech Republic)
• JINYU BIO-TECHNOLOGY CO., LTD (China)
• Phibro Animal Health (U.S.)
• ANHUI TIANKANG(GROUP)SHRES O., LTD (China)
• Zoetis (U.S.)
• WINSUN BIO (China)
• PULIKE BIOLOGICAL ENGINEERING, INC. (China)

INDUSTRIAL DEVELOPMENT

February 2023: The U.S. swine team introduced FLEX CircoPRRS a single-shot safeguard for pigs against both Porcine circovirus type 2 (PCV2) and the causative virus of Porcine reproductive and respiratory syndrome.

Report Coverage 

The report provides an insight into industry from both the demand and supply sides. Further, it also gives information on the impact of COVID-19 on the market, the driving and the restraining factors along with the regional insights. Market dynamic forces during the forecast period have also been discussed for the better understanding of the market situations. The report also lists the key industry players to understand the competition.